RAPT Therapeutics, Inc. (RAPT)

Market Cap	1.78B +1,001.5%
Revenue (ttm)	n/a
Net Income	-105.64M
EPS	-4.88
Shares Out	30.92M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,346,241
Open	57.73
Previous Close	57.75
Day's Range	57.61 - 57.77
52-Week Range	5.67 - 57.80
Beta	0.46
Analysts	Buy
Price Target	56.22 (-2.55%)
Earnings Date	Mar 5, 2026

About RAPT

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company’s lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX47...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 31, 2019
• Employees: 60
• Stock Exchange: NASDAQ
• Ticker Symbol: RAPT
• Website: https://www.rapt.com

Analyst Summary

According to 10 analysts, the average rating for RAPT stock is "Buy." The 12-month stock price target is $56.22, which is a decrease of -2.55% from the latest price.

Price Target

$56.22

(-2.55% downside)

Analyst Consensus: Buy